Nemaura Medical Inc.
NMRD · OTC
12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | -$2 |
| % Growth | – | – | 100% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $3 |
| Gross Profit | -$0 | $0 | $0 | -$5 |
| % Margin | – | – | – | 295.2% |
| R&D Expenses | $0 | $0 | $1 | $1 |
| G&A Expenses | $1 | $2 | $2 | $1 |
| SG&A Expenses | $1 | $2 | $2 | $1 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $1 |
| Operating Expenses | $2 | $2 | $2 | $2 |
| Operating Income | -$2 | -$2 | -$2 | -$4 |
| % Margin | – | – | – | 276% |
| Other Income/Exp. Net | -$1 | $1 | -$1 | -$0 |
| Pre-Tax Income | -$2 | -$1 | -$3 | -$5 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$2 | -$1 | -$3 | -$0 |
| % Margin | – | – | – | 21.1% |
| EPS | -0.075 | -0.042 | -0.09 | -0.013 |
| % Growth | -79.8% | 53.8% | -582.6% | – |
| EPS Diluted | -0.075 | -0.042 | -0.09 | -0.013 |
| Weighted Avg Shares Out | 29 | 29 | 29 | 25 |
| Weighted Avg Shares Out Dil | 29 | 29 | 29 | 25 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $2 | $1 | $1 | $2 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$0 | -$0 | -$2 | -$2 |
| % Margin | – | – | – | 144.7% |